Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer

Cancer Immunology, Immunotherapy

Volumn 64, Issue 9, 2015, Pages 1083-1093

  Zhen, Yun Huan ^a   Liu, Xiao Hui ^a   Yang, Yuan ^a   Li, Bo ^a   Tang, Jing Ling ^a   Zeng, Qiang Xing ^a   Hu, Jie ^a   Zeng, Xing Nan ^a   Zhang, Lu ^b   Wang, Ze Jun ^a   Li, Xiao Yun ^a   Ge, Hui Xin ^a   Winqvist, Ola ^b   Hu, Ping Sheng ^c   Xiu, Jin ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Research and Development   (China)

Author keywords

Adoptive immunotherapy; Colorectal cancer; Phase I II study; Sentinel lymph node; T lymphocytes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FLUOROURACIL; HEMOGLOBIN; IMMUNOLOGICAL ADJUVANT;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL THERAPY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LONG TERM SURVIVAL; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL; ONCOLOGY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SAFETY; SENTINEL LYMPH NODE; STATISTICAL ANALYSIS; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT OUTCOME; CLINICAL TRIAL; COLORECTAL NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPH NODE; PATHOLOGY; PROCEDURES; PROGNOSIS; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES;

EID: 84939566085     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1715-3     Document Type: Article

References (47)

1. Garborg K, Holme O, Loberg M, Kalager M, Adami HO, Bretthauer M (2013) Current status of screening for colorectal cancer. Ann Oncol 24:1963–1972. doi:10.1093/annonc/mdt157
2. Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104–117. doi:10.3322/caac.21220
3. Edwards BK, Ward E, Kohler BA et al (2010) Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544–573. doi:10.1002/cncr.24760
4. Sargent D, Sobrero A, Grothey A et al (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27:872–877. doi:10.1200/JCO.2008.19.5362
5. Lesterhuis WJ, Haanen JB, Punt CJ (2011) Cancer immunotherapy–revisited. Nat Rev Drug Discov 10:591–600. doi:10.1038/nrd3500
6. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480–489. doi:10.1038/nature10673
7. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G (2012) Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology 1:306–315. doi:10.4161/onci.19549
8. Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P (2013) Advances in the development of cancer immunotherapies. Trends Immunol 34:90–98. doi:10.1016/j.it.2012.08.004
9. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM (2001) Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19:2576–2582
10. Jain A, Slansky JE, Matey LC, Allen HE, Pardoll DM, Schulick RD (2003) Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol 10:810–820
11. Mosolits S, Nilsson B, Mellstedt H (2005) Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Exp Rev Vaccin 4:329–350. doi:10.1586/14760584.4.3.329
12. Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM (2005) Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23:2379–2387. doi:10.1016/j.vaccine.2005.01.015
13. Kavanagh B, Ko A, Venook A et al (2007) Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 30:762–772. doi:10.1097/CJI.0b013e318133451c
14. Harris JE, Ryan L, Hoover HC Jr et al (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18:148–157
15. Karlsson M, Marits P, Dahl K, Dagoo T, Enerback S, Thorn M, Winqvist O (2010) Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol 17:1747–1757. doi:10.1245/s10434-010-0920-8
16. Xiang B, Snook AE, Magee MS, Waldman SA (2013) Colorectal cancer immunotherapy. Discov Med 15:301–308
17. Yanagawa E, Uchida A, Micksche M (1984) Natural cytotoxicity of lymphocytes from lymph nodes draining breast carcinoma and its augmentation by interferon and OK432. Cancer Immunol Immunother 17:1–6
18. Yoshizawa H, Chang AE, Shu S (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729–737
19. Kim JA, Bresler HS, Martin EW Jr, Aldrich W, Heffelfinger M, Triozzi PL (1999) Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer 86:22–30
20. Sabel MS, Arora A, Su G, Chang AE (2006) Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor. Cryobiology 53:360–366. doi:10.1016/j.cryobiol.2006.07.004
21. Marits P, Karlsson M, Dahl K, Larsson P, Wanders A, Thorn M, Winqvist O (2006) Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 94:1478–1484. doi:10.1038/sj.bjc.6603126
22. Dahl K, Westlin J, Kraaz W, Winqvist O, Bergkvist L, Thorn M (2005) Identification of sentinel nodes in patients with colon cancer. Eur J Surg Oncol 31:381–385. doi:10.1016/j.ejso.2004.12.015
23. Mitsuma S, Yoshizawa H, Ito K, Moriyama H, Wakabayashi M, Chou T, Arakawa M, Shu S (1994) Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells. Immunology 83:45–51
24. Aruga A, Aruga E, Cameron MJ, Chang AE (1997) Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. J Leukoc Biol 61:507–516
25. Maass G, Schmidt W, Berger M, Schilcher F, Koszik F, Schneeberger A, Stingl G, Birnstiel ML, Schweighoffer T (1995) Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 92:5540–5544
26. Sussman JJ, Parihar R, Winstead K, Finkelman FD (2004) Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion. Cancer Res 64:9124–9130. doi:10.1158/0008-5472.CAN-03-0376
27. Wang LX, Huang WX, Graor H, Cohen PA, Kim JA, Shu S, Plautz GE (2004) Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med 2:41. doi:10.1186/1479-5876-2-41
28. To WC, Wood BG, Krauss JC et al (2000) Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 126:1225–1231
29. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG (2003) Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21:884–890
30. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S (1997) Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15:796–807
31. Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S, Wu X, Liu M, Wang S (2010) Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res 16:4105–4112. doi:10.1158/1078-0432.CCR-10-1073
32. Matera L, Sandrucci S, Mussa A, Boffa C, Castellano I, Cassoni P (2010) Low Foxp3 expression in negative sentinel lymph nodes is associated with node metastases in colorectal cancer. Gut 59:419–420. doi:10.1136/gut.2009.203422
33. Maecker HT, McCoy JP, Nussenblatt R (2012) Standardizing immunophenotyping for the human immunology project. Nat Rev Immunol 12:191–200. doi:10.1038/nri3158
34. Liu W, Putnam AL, Xu-Yu Z et al (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203:1701–1711. doi:10.1084/jem.20060772
35. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. doi:10.1038/nrc3239
36. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466
37. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. doi:10.1056/NEJMoa1200690
38. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294
39. Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2:e26621. doi:10.4161/onci.26621
40. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P (2013) Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 13:15
41. Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39:49–60. doi:10.1016/j.immuni.2013.07.002
42. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281. doi:10.1038/nri3191
43. Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38. doi:10.1126/scitranslmed.3005930
44. Brentjens RJ, Riviere I, Park JH et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:4817–4828. doi:10.1182/blood-2011-04-348540
45. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233–240. doi:10.1016/j.coi.2009.03.002
46. Mulder WM, Stukart MJ, Roos M, van Lier RA, Wagstaff J, Scheper RJ, Bloemena E (1995) Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity. Cancer Immunol Immunother 41:293–301
47. Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, Parisi A, Noya G, Platell C (2012) Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev 8:CD008997. doi:10.1002/14651858.CD008997.pub2